Bennett Levitan

Johnson & Johnson (United States) — United States

Economics, Econometrics and Finance · Social Sciences

24h-index2.0kcitations120works4.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Health Systems, Economic Evaluations, Quality of Life(50), Pharmaceutical industry and healthcare(24), Atrial Fibrillation Management and Outcomes(17), Pharmaceutical Economics and Policy(15), Venous Thromboembolism Diagnosis and Management(13)

Publications120 total

Caution is needed for systematic reviews and interpretation of preference studies
Journal of the European Academy of Dermatology and Venereology·2026
Developing Tools for the Efficient Design of Health Preference Studies: Taxonomy of Attributes and Prototype of an Attribute Library
Patient·2025
Benefit–Risk Assessment of Rivaroxaban in Older Patients With Nonvalvular Atrial Fibrillation or Venous Thromboembolism
Drugs & Aging·2025· 2 citedOpen Access
Quantitative Benefit–Risk Assessment of Vaccination Against <scp>COVID</scp>‐19: A Systematic Review
Pharmacoepidemiology and Drug Safety·2025Open Access
What Next for the Science of Patient Preference? Interoperability, Standardization, and Transferability
Patient·2025· 2 citedOpen Access
First-Line Ibrutinib Plus Venetoclax Vs Chlorambucil Plus Obinutuzumab in Elderly or Comorbid Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): Glow Study 64-Month Follow-up (FU) and Adverse Event (AE)-Free Progression-Free Survival (PFS) Analysis
Blood·2024· 13 citedOpen Access
PCR141 Smoldering Multiple Myeloma: A Multi-Country Mixed-Methods Study on Disease Perceptions and Patient Treatment Preferences
Value in Health·2024Open Access
Quantitative Benefit–Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial
Journal of the American Heart Association·2024· 7 citedOpen Access
A Benefit–Risk Conceptual Framework for Biologic Use During Pregnancy: A Mini‐Review
Clinical Pharmacology & Therapeutics·2024Open Access
How to Present a Decision Object in Health Preference Research: Attributes and Levels, the Decision Model, and the Descriptive Framework
Patient·2024· 18 citedOpen Access
The Brighton collaboration standardized module for vaccine benefit-risk assessment
Vaccine·2023· 13 citedOpen Access
Current Practices and Challenges When Submitting Patient Experience Data for Regulatory Decisions by the US Food and Drug Administration: An Industry Survey
Patient·2023· 7 citedOpen Access
How can patient preferences be used and communicated in the regulatory evaluation of medicinal products? Findings and recommendations from IMI PREFER and call to action
Frontiers in Pharmacology·2023· 19 citedOpen Access
Benefit-risk assessment of vaccines
Vaccine·2023· 8 citedOpen Access
P38 Current Practices and Challenges When Submitting Patient Experience Data for US Regulatory Decision-Making: An Industry Survey
Value in Health·2023Open Access
Quantitative Benefit-Risk Assessment in Medical Product Decision Making: A Good Practices Report of an ISPOR Task Force
Value in Health·2023· 32 citedOpen Access
Illustrating Emerging Good Practices for Quantitative Benefit-Risk Assessment: A Hypothetical Case Study of Systemic Biologic Treatments for Plaque Psoriasis
Value in Health·2023· 4 citedOpen Access
Treatment preferences in relation to fatigue of patients with relapsing multiple sclerosis: A discrete choice experiment
Multiple Sclerosis Journal - Experimental Translational and Clinical·2023· 9 citedOpen Access
Use of Patient Preferences Data Regarding Multiple Risks to Inform Regulatory Decisions
MDM Policy & Practice·2023· 6 citedOpen Access
The relevance of fatigue to relapse rate in multiple sclerosis: Applying patient preference data to the OPTIMUM trial
Multiple Sclerosis Journal·2022· 2 citedOpen Access
page 1 of 6Next →

Frequent Co-authors

Esther W. de Bekker‐Grob(12), Žhong Yuan(12), Chiara Whichello(9), Jorien Veldwijk(8), Isabelle Huys(8), Juhaeri Juhaeri(8), Eline van Overbeeke(7), Irina Cleemput(7), Rosanne Janssens(6), Eva G. Katz(6), Brett Hauber(5), Steven Simoens(5), Jürgen Kübler(5), F. Reed Johnson(5), Cathy Anne Pinto(4), Karin Schölin Bywall(4), Jesse A. Berlin(4), Martin Ho(3), Stephanie Christopher(3), Gary E. Raskob(3)